Market Cap 24.14M
Revenue (ttm) 0.00
Net Income (ttm) -19.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 206,861
Avg Vol 248,416
Day's Range N/A - N/A
Shares Out 32.62M
Stochastic %K 7%
Beta 0.36
Analysts Strong Sell
Price Target $4.53

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 274 7510
Fax: 929 274 7553
Address:
22 Boston Wharf Road, Floor 7, Boston, United States
topstockalerts
topstockalerts Oct. 15 at 5:26 PM
Akari Therapeutics shares fell Wednesday after the oncology biotech announced a registered direct offering of American Depositary Shares (ADS) priced below market value. The company is selling 3,125,000 ADS at $0.80 each, with each ADS representing 2,000 ordinary shares—a discount to recent trading levels that likely triggered the drop. Akari will also issue unregistered warrants in a concurrent private placement: Series E warrants to purchase up to 3,125,000 ADS at $0.98 per share, exercisable after shareholder approval for five years, and Series F warrants with a 30-month term. The company expects to raise about $2.X.5 million in gross proceeds, with closing expected around October 16, 2025. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent. $AKTX
0 · Reply
topstockalerts
topstockalerts Oct. 15 at 5:26 PM
Akari Therapeutics shares fell Wednesday after the oncology biotech announced a registered direct offering of American Depositary Shares (ADS) priced below market value. The company is selling 3,125,000 ADS at $0.80 each, with each ADS representing 2,000 ordinary shares—a discount to recent trading levels that likely triggered the drop. Akari will also issue unregistered warrants in a concurrent private placement: Series E warrants to purchase up to 3,125,000 ADS at $0.98 per share, exercisable after shareholder approval for five years, and Series F warrants with a 30-month term. The company expects to raise about $2.5 million in gross proceeds, with closing expected around October 16, 2025. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent. $AKTX
0 · Reply
coachmc
coachmc Oct. 15 at 1:40 PM
$AKTX rough day. Looks like old rival Omer is celebrating on their good news
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 15 at 1:08 PM
$AKTX (-6.1% pre) Akari Therapeutics raises $2.X.5 million in direct offering https://ooc.bz/l/80608
0 · Reply
Bart69
Bart69 Oct. 15 at 12:38 PM
$AKTX "Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000 of the Company's American Depositary Shares ("ADSs"), each representing 2,000 ordinary shares at a purchase price of $0.80 per ADS in a registered direct offering."
0 · Reply
Bart69
Bart69 Oct. 10 at 2:05 PM
$AKTX Adding below 1 still. Not falling for shake outs.
0 · Reply
bohrsmodel
bohrsmodel Oct. 9 at 3:22 AM
$AKTX Lots of insider purchase and 2 key patents in Asia. Analyst Consensus. Strong Buy. Average Price Target: $4.53
0 · Reply
bohrsmodel
bohrsmodel Oct. 9 at 3:09 AM
$NXL positive clinical trial result and huge insider buy $AKTX secured 2 patent in Asia, lots of insider purchase $PSTV Agreement with United Healthcare. Analyst Price Forecast Suggests 1,132.22% Upside $ATHR.CSE Aether Catalyst Solutions Files Landmark Patent: A Game-Changer for Automotive Emissions and Precious Metal Markets. Imagine no more catalytic converters being stolen anymore. $BUX.CSE Patent approved and test run in Germany on 10,000 people to run lung cancer screening
0 · Reply
jennybaby
jennybaby Oct. 6 at 7:03 PM
$AKTX there is a sector rotation into biotech, especially the beaten up ones. And this turd is barely creeping up. 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️
1 · Reply
stockscan
stockscan Oct. 3 at 2:24 PM
$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-announces-abstract-accepted-oral-presentation
0 · Reply
Latest News on AKTX
Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 22, 2025, 9:05 AM EDT - 5 days ago

Akari Therapeutics Announces Launch of CEO Corner Platform


Akari Therapeutics Announces Key Leadership Appointments

Dec 18, 2024, 8:51 AM EST - 11 months ago

Akari Therapeutics Announces Key Leadership Appointments


Akari Therapeutics to Present at Biotech Showcase 2024

Dec 14, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics to Present at Biotech Showcase 2024


Akari Therapeutics to Present at Emerging Growth Conference

Sep 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Present at Emerging Growth Conference


Akari Therapeutics, Plc Announces ADS Ratio Change

Aug 15, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics, Plc Announces ADS Ratio Change


topstockalerts
topstockalerts Oct. 15 at 5:26 PM
Akari Therapeutics shares fell Wednesday after the oncology biotech announced a registered direct offering of American Depositary Shares (ADS) priced below market value. The company is selling 3,125,000 ADS at $0.80 each, with each ADS representing 2,000 ordinary shares—a discount to recent trading levels that likely triggered the drop. Akari will also issue unregistered warrants in a concurrent private placement: Series E warrants to purchase up to 3,125,000 ADS at $0.98 per share, exercisable after shareholder approval for five years, and Series F warrants with a 30-month term. The company expects to raise about $2.X.5 million in gross proceeds, with closing expected around October 16, 2025. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent. $AKTX
0 · Reply
topstockalerts
topstockalerts Oct. 15 at 5:26 PM
Akari Therapeutics shares fell Wednesday after the oncology biotech announced a registered direct offering of American Depositary Shares (ADS) priced below market value. The company is selling 3,125,000 ADS at $0.80 each, with each ADS representing 2,000 ordinary shares—a discount to recent trading levels that likely triggered the drop. Akari will also issue unregistered warrants in a concurrent private placement: Series E warrants to purchase up to 3,125,000 ADS at $0.98 per share, exercisable after shareholder approval for five years, and Series F warrants with a 30-month term. The company expects to raise about $2.5 million in gross proceeds, with closing expected around October 16, 2025. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent. $AKTX
0 · Reply
coachmc
coachmc Oct. 15 at 1:40 PM
$AKTX rough day. Looks like old rival Omer is celebrating on their good news
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 15 at 1:08 PM
$AKTX (-6.1% pre) Akari Therapeutics raises $2.X.5 million in direct offering https://ooc.bz/l/80608
0 · Reply
Bart69
Bart69 Oct. 15 at 12:38 PM
$AKTX "Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000 of the Company's American Depositary Shares ("ADSs"), each representing 2,000 ordinary shares at a purchase price of $0.80 per ADS in a registered direct offering."
0 · Reply
Bart69
Bart69 Oct. 10 at 2:05 PM
$AKTX Adding below 1 still. Not falling for shake outs.
0 · Reply
bohrsmodel
bohrsmodel Oct. 9 at 3:22 AM
$AKTX Lots of insider purchase and 2 key patents in Asia. Analyst Consensus. Strong Buy. Average Price Target: $4.53
0 · Reply
bohrsmodel
bohrsmodel Oct. 9 at 3:09 AM
$NXL positive clinical trial result and huge insider buy $AKTX secured 2 patent in Asia, lots of insider purchase $PSTV Agreement with United Healthcare. Analyst Price Forecast Suggests 1,132.22% Upside $ATHR.CSE Aether Catalyst Solutions Files Landmark Patent: A Game-Changer for Automotive Emissions and Precious Metal Markets. Imagine no more catalytic converters being stolen anymore. $BUX.CSE Patent approved and test run in Germany on 10,000 people to run lung cancer screening
0 · Reply
jennybaby
jennybaby Oct. 6 at 7:03 PM
$AKTX there is a sector rotation into biotech, especially the beaten up ones. And this turd is barely creeping up. 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️
1 · Reply
stockscan
stockscan Oct. 3 at 2:24 PM
$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-announces-abstract-accepted-oral-presentation
0 · Reply
2pumps1dump
2pumps1dump Sep. 29 at 3:01 PM
0 · Reply
StockScanners
StockScanners Sep. 26 at 5:16 AM
$AKTX reached 1.24
0 · Reply
Tidewater1980
Tidewater1980 Sep. 26 at 2:16 AM
$LAC $AKTX Bring The Juice
0 · Reply
2pumps1dump
2pumps1dump Sep. 25 at 2:59 PM
$AKTX still early
0 · Reply
SMARTR8
SMARTR8 Sep. 25 at 2:16 PM
$AKTX BANGGGG 🤝🤝🤝✅️✅️✅️✅️⬇️⬇️⬇️⬇️
0 · Reply
2pumps1dump
2pumps1dump Sep. 25 at 8:50 AM
$AKTX 🧐 come on.
0 · Reply
StockScanners
StockScanners Sep. 25 at 1:07 AM
$AKTX keep watch if this holds above 1.05
0 · Reply
BearishAlgo
BearishAlgo Sep. 25 at 1:03 AM
Wednesday 2025-09-24 Recap: $OFAL -5.71% ❌ $PEPG -7.11% ❌ $TKNO -2.56% ❌ $AKTX +6.67% ✅ $CRE +20.65% ✅
0 · Reply
BearishAlgo
BearishAlgo Sep. 25 at 12:36 AM
$AKTX Rejected the zone, never broke the upper boundary, dropped from 1.20 to 1.05, closed at 1.12. NEWS: phase1 preclinical data release
0 · Reply
IntraTrades
IntraTrades Sep. 25 at 12:02 AM
$SLNH 60.18% $DBGI 43.75% $PEPG 36.41% $AKTX 35.27% $ATCH 30.86%
0 · Reply
jennybaby
jennybaby Sep. 24 at 11:09 PM
$AKTX this is the first time in bazillions that AKTX held the gains with 3.67 mill shares traded. I hope to see some continuation. I did unload 5k shares for a puny profit and I am still holding 11.2k shares. Peanuts compared to what I had once and I am totally cool with that.
0 · Reply
VolcanicTrades
VolcanicTrades Sep. 24 at 10:44 PM
$AKTX keep an eye. Called a pretty close bottom on $CDLX as well
0 · Reply